Physician profile
Jonathan Aronbayev
NPI 1750318721
$2,689.96
in general payments reported to CMS, 2019-2025
24 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $70.33 · 2021: $246 · 2022: $145 · 2023: $265 · 2024: $980 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.66 | 2020-2025 | Viberzi, Linzess, Qulipta |
| Aimmune Therapeutics, INC. | $305.00 | 2024-2025 | Zenpep, Vowst |
| Novo Nordisk INC | $289.15 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $158.30 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.92 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $131.27 | 2021-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $119.40 | 2019 | |
| Scilex Pharmaceuticals INC. | $101.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $80.51 | 2021-2023 | |
| Pfizer INC. | $80.21 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $68.19 | 2024 | Nuzyra |
| Ardelyx, INC. | $51.33 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $46.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.92 | 2024-2025 | Camzyos |
| Ironwood Pharmaceuticals, INC | $41.41 | 2019-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $38.74 | 2024 | Nexletol |
| Gilead Sciences, INC. | $31.41 | 2024 | |
| Exact Sciences Corporation | $30.58 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $30.50 | 2019-2020 | |
| Abbott Laboratories | $26.91 | 2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $26.47 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $25.01 | 2025 | Farxiga |
| Glaxosmithkline, LLC. | $23.53 | 2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $19.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Aronbayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.